BioCardia FY 2025 net loss rises 3.8% to $8.2 million on $2.5 million cash balance

BioCardia, Inc.

BioCardia, Inc.

BCDA

0.00
  • BioCardia published its annual report on Form 10-K reporting full-year financial results.
  • Net loss was USD 8.2 million, up 3.8%.
  • Net cash used in operations was USD 7.4 million, down 6.3%, primarily due to the timing of supplier payments.
  • Research and development expense rose to USD 5.0 million, up 13.6%, driven by closeout activities in the CardiAMP Heart Failure Trial, initiation of enrollment in the CardiAMP Heart Failure II Trial and regulatory activities to advance CardiAMP in Japan.
  • Cash and cash equivalents were USD 2.5 million, and management said it expects upcoming milestones including an FDA Q-Sub on the CardiAMP approval pathway in Q1 2026 and an FDA pre-submission meeting for the Helix delivery catheter in Q2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603241605PRIMZONEFULLFEED9677857) on March 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.